Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, October 2, 2017
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
[ Mon, Oct 02nd 2017
] - WOPRAI
Matthew Harrison Upgraded (SRPT) to Buy on, Oct 2nd, 2017
Matthew Harrison of Morgan Stanley, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, Oct 2nd, 2017.
Matthew has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Initiated at Hold and Held Target at $46 on, Thursday, September 7th, 2017
This is the rating of the analyst that currently disagrees with Matthew
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017
Similar Stocks and Investing Articles
[ Tue, Sep 12th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Thu, Sep 07th 2017
] - WOPRAI
[ Wed, Jan 04th 2017
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Wed, Oct 08th 2014
] - WOPRAI
[ Tue, Oct 01st 2013
] - WOPRAI
[ Mon, Jan 07th 2013
] - WOPRAI
[ Mon, Nov 05th 2012
] - WOPRAI